SCHEMBL16405264

SCHEMBL16405264

O=C(CCCCCC(=O)CCN1C(=O)C=CC1=O)CCN1C(=O)C=CC1=O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 7/20 0.63
PTGS2 P35354 7/20 0.63
MGLL Q99685 9/20 0.58
FAAH O00519 4/20 0.58
ALDH1A1 P00352 3/20 0.58
LMNA P02545 2/20 0.58
MAPT P10636 2/20 0.58
NPSR1 Q6W5P4 2/20 0.58
HPGD P15428 2/20 0.58
HSP90AA1 P07900 1/20 0.58
TLR9 Q9NR96 1/20 0.58
TP53 P04637 1/20 0.58
PKM P14618 1/20 0.58
XBP1 P17861 1/20 0.58
MAPK1 P28482 1/20 0.58
HTT P42858 1/20 0.58
RECQL P46063 1/20 0.58
RAB9A P51151 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
GPR35 Q9HC97 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22353278 0.91 PTGS1 (0.65) PTGS1PTGS2MGLLFAAHALDH1A1
SCHEMBL29044909 0.89 MGLL (0.54) PTGS1PTGS2MGLLFAAHALDH1A1
SCHEMBL16405262 0.89 MGLL (0.54) PTGS1PTGS2MGLLFAAHALDH1A1
SCHEMBL17972723 0.87 PTGS1 (0.50) PTGS1PTGS2MGLLFAAHALDH1A1
SCHEMBL2222522 0.85 PTGS1 (0.89) PTGS1PTGS2MGLLFAAHALDH1A1
SCHEMBL20621983 0.83 MGLL (0.70) PTGS1PTGS2MGLLFAAHALDH1A1
SCHEMBL29064048 0.83 PTGS1 (0.64) PTGS1PTGS2MGLLFAAHALDH1A1
SCHEMBL16274103 0.83 MGLL (0.65) PTGS1PTGS2MGLLFAAHALDH1A1
SCHEMBL13543586 0.83 MGLL (0.70) PTGS1PTGS2MGLLFAAHALDH1A1
SCHEMBL17570363 0.83 PTGS1 (0.48) PTGS1PTGS2MGLLFAAHALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227799-A1 MODIFIED HELICASES OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2023-07-20 US disclosed
US-20230212535-A1 MODIFIED HELICASES OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2023-07-06 US disclosed
US-20180037874-A9 MODIFIED HELICASES OXFORD NANOPORE TECHNOLOGIES LTD. (GB) 2018-02-08 US disclosed
US-9797009-B2 Enzyme construct OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) 2017-10-24 US disclosed
US-9636418-B2 Potent and selective inhibitors of NAV1.7 AMGEN INC. (US) 2017-05-02 US disclosed
US-20160257942-A1 MODIFIED HELICASES OXFORD NANOPORE TECHNOLOGIES LTD. (GB) 2016-09-08 US disclosed
US-20150218629-A1 ENZYME CONSTRUCT OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) 2015-08-06 US disclosed
US-20150197796-A1 SSB METHOD OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) 2015-07-16 US disclosed
US-20150191709-A1 MODIFIED HELICASES OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) 2015-07-09 US disclosed
US-20150023988-A1 POTENT AND SELECTIVE INHIBITORS OF NAV1.7 AMGEN INC. (US) 2015-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150023988-A1 POTENT AND SELECTIVE INHIBITORS OF NAV1.7 SCN7A, SCN9A, SCN1A PTGS1 2922/4885PTGS2 3218/4885MGLL 4337/4885
US-20150218629-A1 ENZYME CONSTRUCT DCLRE1B, DNA2, WRN PTGS1 3233/4885PTGS2 3120/4885MGLL 2286/4885
US-20230227799-A1 MODIFIED HELICASES DDX21, DDX5, DDX17 PTGS1 3466/4885PTGS2 3570/4885MGLL 3782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.